期刊文献+

Impact of crosslinking/riboflavin-UVA-photodynamic inactivation on viability,apoptosis and activation of human keratocytes in vitro 被引量:2

Impact of crosslinking/riboflavin-UVA-photodynamic inactivation on viability, apoptosis and activation of human keratocytes in vitro
下载PDF
导出
摘要 Riboflavin-UVA photodynamic inactivation is a potential treatment altemative in therapy resistant infectious keratitis. The purpose of our study was to determine the impact of riboflavin-UVA photodynamic inactivation on viability, apop- tosis and activation of human keratocytes in vitro. Primary human keratocytes were isolated from human corneal buttons and cultured in DMEM/Ham's F12 medium supplemented with 10% fetal calf serum. Keratocytes underwent UVA light illumination (375 nm) for 4.10 minutes (2 J/cm2) during exposure to different concentrations of riboflavin. Twenty-four hours after treatment, cell viability was evaluated photometrically, whereas apoptosis, CD34 and alpha-smooth muscle actin (α-SMA) expression were assessed using flow cytometry. We did not detect significant changes in cell viability, apoptosis, CD34 and α-SMA expression in groups only treated with riboflavin or UVA light. In the group treated with riboflavin-UVA-photodynamic inactivation, viability of keratocytes decreased significantly at 0.1% riboflavin (P〈0.01) while the percentage of CD34 (P〈0.01 for both 0.05% and 0.1% riboflavin) and alpha-SMA positive keratocytes (P〈0.01 and P〈0.05 for 0.05% and 0.1% riboflavin, respectively) increased significantly compared to the controls. There was no significant change in the percentage of apoptotic keratocytes compared to controls at any of the used ribo- flavin concentrations (P=0.09 and P=0.13). We concluded that riboflavin-UVA-photodynamic-inactivation decreases viability of myofibroblastic transformation and multipotent haematopoietic stem cell transformation; however, it does not have an impact on apoptosis of human keratocytes in vitro. Riboflavin-UVA photodynamic inactivation is a potential treatment altemative in therapy resistant infectious keratitis. The purpose of our study was to determine the impact of riboflavin-UVA photodynamic inactivation on viability, apop- tosis and activation of human keratocytes in vitro. Primary human keratocytes were isolated from human corneal buttons and cultured in DMEM/Ham's F12 medium supplemented with 10% fetal calf serum. Keratocytes underwent UVA light illumination (375 nm) for 4.10 minutes (2 J/cm2) during exposure to different concentrations of riboflavin. Twenty-four hours after treatment, cell viability was evaluated photometrically, whereas apoptosis, CD34 and alpha-smooth muscle actin (α-SMA) expression were assessed using flow cytometry. We did not detect significant changes in cell viability, apoptosis, CD34 and α-SMA expression in groups only treated with riboflavin or UVA light. In the group treated with riboflavin-UVA-photodynamic inactivation, viability of keratocytes decreased significantly at 0.1% riboflavin (P〈0.01) while the percentage of CD34 (P〈0.01 for both 0.05% and 0.1% riboflavin) and alpha-SMA positive keratocytes (P〈0.01 and P〈0.05 for 0.05% and 0.1% riboflavin, respectively) increased significantly compared to the controls. There was no significant change in the percentage of apoptotic keratocytes compared to controls at any of the used ribo- flavin concentrations (P=0.09 and P=0.13). We concluded that riboflavin-UVA-photodynamic-inactivation decreases viability of myofibroblastic transformation and multipotent haematopoietic stem cell transformation; however, it does not have an impact on apoptosis of human keratocytes in vitro.
出处 《The Journal of Biomedical Research》 CAS CSCD 2015年第4期321-325,共5页 生物医学研究杂志(英文版)
基金 supports of the China Scholarship Council(CSC)for the author's study(J Wang and X Song) the Alexander von Humboldt Foundation for supporting the work of Dr.N.Szentmary at the Department of Ophthalmology of Saarland University,Homburg/Saar,Germany supported by"Zentrales Innovationsprogram Mittelstand(ZIM)"of the German Federal Ministry of Economics and Technology(Project number:KF2152004MD0)
关键词 CROSSLINKING human keratocytes VIABILITY APOPTOSIS A-SMA CD34 crosslinking, human keratocytes, viability, apoptosis, a-SMA, CD34
  • 相关文献

参考文献23

  • 1Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy[J]. J Natl Cancer Inst, 1998,90: 889-905.
  • 2Szentmhry N, Goebels S, Bischoff M, Seitz B. Photodynamic therapy for infectious keratitis[J]. Ophthalmologe, 2012, 109(2):165-170.
  • 3Fimple JL, Fontana CR, Foschi F, et al. Photodynamic treatment of endodontic polymicrobial infection in vitro[J]. J Endod, 2008,34(6):728-734.
  • 4Martins SA, Combs JC, Noguera G, et al. Antimicrobial efficacy of riboflavin/UVA combination (365 nm) in vitro for bacterial and fungal isolates: a potential new treatment for infectious keratitis[J]. Invest Ophthalmol Vis Sci, 2008, 49(8):3402-3408.
  • 5Khan YA, Kashiwabuchi RT, Martins SA, et al. Riboflavin and ultraviolet light a therapy as an adjuvant treatment for medically refractive Acanthamoeba keratitis: report of 3 cases[J]. Ophthalmology, 2011,118(2):324- 331.
  • 6Goto B, Iriuchishima T, Horaguchi T, et al. Therapeutic effect of photodynamic therapy using Na-pheophorbide a on osteomyelitis models in rats[J]. Photomed Laser Surg, 2011,29(3):183-189.
  • 7Lang GE. Photodynamische Therapie in der Augen- heilkunde[M]. Springer Verlag, 1st Edition, Heidelberg 2008,1-5.
  • 8Cursiefen C. Corneal crosslinking: "Safe and effecfive"[J]? Ophthalmologe, 2009,106(2):164-5; author reply 65-66.
  • 9Kymionis GD, Portaliou DM, Bouzoukis DI, et al. Herpetic keratitis with iritis after corneal crosslinking withriboflavin and ultraviolet A for keratoconus[J]. J Cataract Refract Surg, 2007,33(11):1982-1984.
  • 10Kymionis GD, Bouzoukis DI, Diakonis VF, et al. Diffuse lamellar keratitis after corneal crosslinking in a patient with post-laser in situ keratomileusis corneal ectasia[J]. J Cataract Refract Surg, 2007,33(12):2135-2137.

同被引文献3

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部